EMVision Medical Devices (ASX:EMV) said that its first responder proof-of-concept device was tested in aeromedical retrieval environment settings, in collaboration with the Royal Flying Doctor Service and the Australian Stroke Alliance, according to a Wednesday Australian bourse filing.
The RFDS staff received preliminary training in the operation of the device with scans completed under an existing ethics approval. The device withstood the physical stress, environmental conditions, and operational constraints related to aeromedical retrieval.
It submitted an ethics application for the RFDS staff to enroll and scan patients in a usability and workflow implementation study set for the coming weeks.
The study will look at the device's usability, reliability, functionality, workflow metrics, among other tests.
Product development activities are underway to transition from advanced prototype proof-of-concept devices to production-equivalent commercial devices.
Another ethics application is underway for the use of the EMVision first responder scans during acute suspected stroke cases attended by the Melbourne Mobile Stroke Unit.
Its shares rose 5% in recent trading on Wednesday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。
没有相关数据
如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”